Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ozlem Goker-Alpan

Pediatrics Fairfax, VA Medical Doctor

NPI 1427270313 CMS profile 336930

11212 Waples Mill Rd Ste 100, Fairfax, VA 22030

Open in the dashboard

General payments

$210,197

180 records reported · program years 2019–2025

Research payments

$12,873

Paid to them · 39 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,354,401 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ozlem Goker-Alpan of Fairfax, VA is reported in the CMS Open Payments database as having received $210,197 across 180 general payments and $12,873 in research payments paid to them. Separately, studies naming them as principal investigator received $8,354,401 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,292 36
2025 Research $88 1
2024 General $20,904 21
2024 Research $110 1
2023 General $35,762 22
2023 Research $750 2
2022 General $12,525 13
2022 Research $4,250 7
2021 General $25,532 15
2021 Research $4,250 10
2020 General $15,943 17
2020 Research $2,007 10
2019 General $58,240 56
2019 Research $1,419 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ozlem Goker-Alpan
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ozlem Goker-Alpan were reported at $41,292. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ozlem Goker-Alpan Pediatrics median Middle half National median
2019 $58,240 $86 $31–$183 $163
2020 $15,943 $49 $22–$110 $114
2021 $25,532 $68 $27–$158 $132
2022 $12,525 $77 $30–$173 $149
2023 $35,762 $88 $33–$190 $160
2024 $20,904 $94 $34–$206 $164
2025 $41,292 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $85,968 69 payments
  2. Shire North American Group Inc $48,903 34 payments
  3. Chiesi USA, Inc. $29,795 26 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $27,834 29 payments
  5. Eli Lilly and Company $7,020 3 payments
  6. Spark Therapeutics, Inc. $5,093 7 payments
  7. Amicus Therapeutics, Inc. $2,947 7 payments
  8. Ultragenyx Pharmaceutical Inc. $2,596 1 payment
  9. IntraBio Inc $25 1 payment
  10. Retrophin, Inc. $17 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100,215 44 payments
  2. Consulting Fee $57,720 24 payments
  3. Travel and Lodging $41,073 43 payments
  4. Honoraria $7,583 6 payments
  5. Food and Beverage $3,601 61 payments
  6. Education $6 2 payments
Products named General payments · program years 2019–2025
  1. ELFABRIO $29,795 26 payments
  2. VPRIV $25,136 30 payments
  3. CEREZYME $12,219 9 payments
  4. FABRAZYME Genetic Disease $9,910 12 payments
  5. NEXVIAZYME $8,620 6 payments
  6. CERDELGA $6,411 8 payments
  7. FABRAZYME Rare Disease Genetics $5,056 9 payments
  8. LUMIZYME Genetic Disease $4,435 4 payments
  9. NO PRODUCT DISCUSSED $1,600 1 payment
  10. LUMIZYME Rare Disease Genetics $1,600 2 payments
  11. Other $2,342 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $12,676 37 payments
  2. Eli Lilly and Company $197 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

132

Median for Pediatric Medicine: 38

Drug cost

$3,920,086

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Elfabrio Pegunigalsidase Alfa-Iwxj Brand 44 $1,522,345
Fabrazyme Agalsidase Beta Brand 52 $975,898
Cerdelga Eliglustat Tartrate Brand 23 $722,603
Pombiliti Cipaglucosidase Alfa-Atga Brand 13 $699,241

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$829,912

Of which drugs: $784,513

Medicare patients

32

Average age 65

Services billed

6,254

20 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 50%
Arthritis 50%
Depression 38%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELFABRIO
  • CHIESI USA, INC. $9,182
$9,182 44 —
FABRAZYME
  • GENZYME CORPORATION $6,603
$6,603 52 —
CEREZYME
  • GENZYME CORPORATION $4,433
$4,433 — —
ALDURAZYME
  • GENZYME CORPORATION $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record